Omega Diagnostics – Development Update
Omega Diagnostics Group PLC – Development Update – Visitect® CD4 and Allergy Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following development update on its infectious disease and allergy projects…. Read More
Omega Diagnostics – Trading Update
Trading Update and Notice of Results Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that results for the year to 31 March 2014 will be in line with market expectations. Revenues… Read More
Omega Diagnostics
CD4 Update – Successful completion of Technology Transfer – Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the successful completion of its CD4 technology transfer project with first in-field evaluations to… Read More
Omega Diagnostics
positive CD4 batch results
Omega Diagnostics
Omega Diagnostics: ‘majority’ of CD4 manufacturing variants eliminated
Omega Diagnostics
Parkwalk closes Omega Diagnostic plc investment Omega Diagnostics is focused on selling a wide range of specialist products, primarily in the immunoassay, in-vitro diagnostics (IVD) market within three segments: Allergy and Autoimmune, Food Intolerance and Infectious Disease. The… Read More
